» Authors » Ryosuke Mori

Ryosuke Mori

Explore the profile of Ryosuke Mori including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 42
Citations 216
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Takei J, Maeda M, Fukasawa N, Kawashima M, Miyake M, Tomoto K, et al.
Brain Tumor Pathol . 2024 Aug; 41(3-4):97-108. PMID: 39186169
Histopathologic examinations of primary central nervous system lymphoma (PCNSL) reveal concentric accumulation of lymphocytes in the perivascular area with fibrosis. However, the nature of this fibrosis in "stiff" PCNSL remains...
2.
Mizuta K, Mori R, Han Q, Morinaga S, Sato M, Kang B, et al.
Cancer Diagn Progn . 2024 Jul; 4(4):402-407. PMID: 38962551
Background/aim: Androgen-independent prostate cancer (AIPC) is resistant to androgen-depletion therapy and is a recalcitrant disease. Docetaxel is the first-line treatment for AIPC, but has limited efficacy and severe side-effects. All...
3.
Goto S, Ozaki Y, Mori R, Ozawa F, Obayashi Y, Kitaori T, et al.
J Reprod Immunol . 2024 Jun; 164:104270. PMID: 38878627
Matrix metalloproteinases (MMPs) degrade extracellular matrix proteins and are important for placenta formation during early pregnancy. Recurrent pregnancy loss (RPL) is associated with abnormalities in endometrial extracellular matrix remodeling. This...
4.
Sato M, Mizuta K, Han Q, Morinaga S, Kang B, Kubota Y, et al.
In Vivo . 2024 Apr; 38(3):1058-1063. PMID: 38688611
Background/aim: Colorectal cancer (CRC) is the third-leading cause of death in the world. Although the prognosis has improved due to improvement of chemotherapy, metastatic CRC is still a recalcitrant disease,...
5.
Sato M, Han Q, Mizuta K, Mori R, Kang B, Morinaga S, et al.
In Vivo . 2024 Apr; 38(3):1459-1464. PMID: 38688589
Background/aim: Gliomas are the most common and recalcitrant malignant primary brain tumors. All cancer types are addicted to methionine, which is a fundamental and general hallmark of cancer known as...
6.
Sato M, Han Q, Mori R, Mizuta K, Kang B, Morinaga S, et al.
Anticancer Res . 2024 Mar; 44(4):1499-1504. PMID: 38538002
Background/aim: Breast cancer is the most common and the deadliest cancer among women in the world. Treatment options for HER2-positive metastatic breast cancer patients are limited. Trastuzumab deruxtecan (T-DXd), an...
7.
Maeda-Anezaki M, Omura K, Mori R, Ishida K
BMJ Case Rep . 2024 Mar; 17(3). PMID: 38479825
We report the first case of a juvenile nasal angiofibroma (JNA) fed by multiple arteries from the internal carotid artery (ICA), removed without complications by temporarily blocking the ICA with...
8.
Ye Y, Kawaguchi Y, Takeuchi A, Zhang N, Mori R, Mijiti M, et al.
Nutr Res . 2023 Sep; 119:76-89. PMID: 37757642
Obesity presents a major risk factor in the development of cardiovascular diseases. Recent reports indicate that many kinds of polyphenols have the potential to prevent metabolic diseases. We hypothesized that...
9.
Takeuchi A, Ye Y, Takada K, Mori R, Nakamura T, Oda N, et al.
Biosci Biotechnol Biochem . 2023 Sep; 87(11):1345-1353. PMID: 37667492
Dietary protein-derived peptides are effective in improving dyslipidemia and hypercholesterolemia. We previously identified a novel cholesterol-lowering pentapeptide IIAEK from milk beta-lactoglobulin. However, it remains unclear whether IIAEK affects the micellar...
10.
Takei J, Kamata Y, Tanaka T, Fukasawa N, Gomisawa K, Satake M, et al.
Cancer Immunol Immunother . 2023 Jun; 72(10):3175-3189. PMID: 37382632
Dendritic cell (DC)-based immunotherapy has been applied to glioblastoma (GBM); however, biomarkers informing response remain poorly understood. We conducted a phase I/IIa clinical trial investigating tumor-fused DC (TFDC) immunotherapy following...